Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of in vitro fertilization in a concentration-dependent manner
Objective
To determine an optimal serum E2 level on the day of hCG administration in controlled ovarian hyperstimulation (COH) during IVF-ET without compromising pregnancy outcome.
Design
Retrospective study.
Setting
Large urban medical center.
Patient(s)
Data of 455 cycles of fresh IVF-ET with COH.
Intervention(s)
Serum E2 levels on the day of hCG administration were categorized into five groups: group A (<1000 pg/mL), group B (1000–2000 pg/mL), group C (2000–3000 pg/mL), group D (3000–4000 pg/mL), and group E (>4000 pg/mL).
Main Outcome Measure(s)
Serum E2 levels, number of oocytes retrieved, pregnancy outcomes.
Result(s)
Of 455 cycles, 148 (32.5%) cycles resulted in clinical pregnancy. The implantation rate was 12.2%, and the delivery rate was 18.7%. The number of oocytes obtained increased with increasing serum E2 levels. The pregnancy rate gradually increased from group A to D as E2 levels increased but decreased in group E. In women <38 years, the IVF-ET outcomes were similar to those of total patients. However, in women ≥38 years old, pregnancy and delivery rates were higher in group C than in other groups.
Conclusion(s)
These results show that serum E2 levels have a concentration-dependent effect on the pregnancy outcome, suggesting an optimal range of E2 level for achieving a successful pregnancy. This optimal range of serum E2 level in women is age dependent: 3000–4000 pg/mL for women <38 years and 2000–3000 pg/mL for women ≥38 years.
Key Words: IVF-ET, controlled ovarian hyperstimulation, serum E2 levels, pregnancy outcome
To access this article, please choose from the options below
B.S.J. has nothing to disclose. S.H.P. has nothing to disclose. B.M.A. has nothing to disclose. K.S.K. has nothing to disclose. S.E.M. has nothing to disclose. H.S.M. has nothing to disclose.
PII: S0015-0282(09)00493-2
doi:10.1016/j.fertnstert.2009.02.066
© 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

